NasdaqCM:CMPXBiotechs
Compass Therapeutics (CMPX) Is Down 65.4% After Tovecimig Combo Meets Key BTC Trial Endpoints - What's Changed
In April 2026, Compass Therapeutics reported that its Phase 2/3 COMPANION-002 trial in advanced biliary tract cancer met the primary endpoint of overall response rate and a key secondary endpoint of progression-free survival for tovecimig plus paclitaxel versus paclitaxel alone, with no new safety concerns observed.
An intriguing finding was that patients who crossed over from paclitaxel alone to the tovecimig combination lived longer than those who stayed on paclitaxel, despite initially...